Premium
Casein glycomacropeptide for active distal ulcerative colitis: a randomized pilot study
Author(s) -
Hvas Christian L.,
Dige Anders,
Bendix Mia,
Wernlund Pernille G.,
Christensen Lisbet A.,
Dahlerup Jens F.,
Agnholt Jørgen
Publication year - 2016
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12634
Subject(s) - ulcerative colitis , medicine , gastroenterology , randomized controlled trial , casein , clinical trial , disease , chemistry , organic chemistry
Background In ulcerative colitis ( UC ), dietary supplements may have anti‐inflammatory properties and improve disease course. We investigated the effects of casein glycomacropeptide ( CGMP ), a fraction of bovine whey protein, in active UC . Materials and methods In a randomized open‐label intervention study, 24 patients with active UC involving 10–40 cm of the distal colon were randomized in a 2 : 1 ratio into two groups. The first group was administered their usual treatment plus a daily supplement of CGMP 30 g, and the second group was administered a dose escalation to 4800 mg oral mesalamine daily (standard treatment) for 4 weeks. Clinical, endoscopic, mucosal and circulating disease activity markers were monitored. Acceptance of and adherence to CGMP up to 8 weeks were documented. Results After 4 weeks of treatment, 10 of 16 (63%) patients who received CGMP had an unchanged or decreased Simple Clinical Colitis Activity Index ( SCCAI ), which was similar to the four of eight (50%) ( P = 0·67) patients on the standard treatment. The number of patients in which SCCAI decreased by three or more did not differ between the two groups: nine of 16 (56%) in the CGMP group vs. four of eight (50%) in the standard treatment group ( P = 0·77). Changes in disease extent and severity were similar between the two groups. CGMP was well tolerated and accepted by the patients. Conclusions The addition of CGMP as a nutritional therapy to standard treatment was safe and accepted by patients with active distal UC . The disease‐modifying effect of CGMP was similar to that of the mesalamine dose escalation.